MX336187B - Metodo para tratar el mal de parkinson. - Google Patents

Metodo para tratar el mal de parkinson.

Info

Publication number
MX336187B
MX336187B MX2012010161A MX2012010161A MX336187B MX 336187 B MX336187 B MX 336187B MX 2012010161 A MX2012010161 A MX 2012010161A MX 2012010161 A MX2012010161 A MX 2012010161A MX 336187 B MX336187 B MX 336187B
Authority
MX
Mexico
Prior art keywords
dosage form
amount ranging
carbidopa
inhibitor
weight
Prior art date
Application number
MX2012010161A
Other languages
English (en)
Spanish (es)
Other versions
MX2012010161A (es
Inventor
Pekka Männistö
Juha Rouru
Mikko Kuoppamäki
Juha Ellmen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Publication of MX2012010161A publication Critical patent/MX2012010161A/es
Publication of MX336187B publication Critical patent/MX336187B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2012010161A 2010-03-04 2011-03-03 Metodo para tratar el mal de parkinson. MX336187B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31039810P 2010-03-04 2010-03-04
US41282110P 2010-11-12 2010-11-12
US201161438416P 2011-02-01 2011-02-01
PCT/FI2011/000013 WO2011107653A2 (en) 2010-03-04 2011-03-03 Method for treating parkinson's disease

Publications (2)

Publication Number Publication Date
MX2012010161A MX2012010161A (es) 2012-10-03
MX336187B true MX336187B (es) 2016-01-07

Family

ID=44065577

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010161A MX336187B (es) 2010-03-04 2011-03-03 Metodo para tratar el mal de parkinson.

Country Status (14)

Country Link
US (4) US20130137729A1 (Direct)
EP (1) EP2542220B1 (Direct)
JP (2) JP5774610B2 (Direct)
KR (1) KR101868326B1 (Direct)
CN (1) CN102781424B (Direct)
AU (1) AU2011222856B2 (Direct)
BR (1) BR112012018256A8 (Direct)
CA (1) CA2784819C (Direct)
EA (1) EA026419B1 (Direct)
ES (1) ES2614179T3 (Direct)
IL (1) IL221744A (Direct)
MX (1) MX336187B (Direct)
WO (1) WO2011107653A2 (Direct)
ZA (1) ZA201205836B (Direct)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
WO2008094053A1 (en) 2007-01-31 2008-08-07 Bial-Portela & Ca, S.A. Dosage regimen for comt inhibitors
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
KR102023255B1 (ko) 2009-04-01 2019-09-19 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
CA2784819C (en) * 2010-03-04 2018-02-13 Orion Corporation Use of levodopa, carbidopa and entacapone for treating parkinson's disease
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
BR112014014341A2 (pt) 2011-12-13 2017-08-22 Bial Portela & Ca Sa Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
CN104884064A (zh) 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
US9642810B2 (en) 2013-03-15 2017-05-09 Mylan Inc. Formulation containing carbidopa, levodopa, and entacapone
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
EP3696182A1 (en) * 2015-08-27 2020-08-19 Prexton Therapeutics SA Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
IL277553B2 (en) * 2018-03-23 2024-11-01 Lobsor Pharmaceuticals Ab Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
TW202031265A (zh) 2018-11-15 2020-09-01 美商艾伯維有限公司 用於皮下投藥之醫藥調配物
CN112741808B (zh) * 2019-10-29 2024-02-06 南京济群医药科技股份有限公司 一种提高含盐酸苄丝肼口服固体组合物稳定性的方法
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
US20230181493A1 (en) * 2020-04-10 2023-06-15 Senda Biosciences, Inc. Biomarkers related to parkinson's disease and methods of using the same
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3462536A (en) 1960-07-22 1969-08-19 Merck & Co Inc Method of inhibiting decarboxylase
DK175069B1 (da) 1986-03-11 2004-05-24 Hoffmann La Roche Pyrocatecholderivater
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd L‐ドーパ誘導体
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5607969A (en) 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
GB2344819A (en) 1998-12-18 2000-06-21 Portela & Ca Sa 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US20080076825A1 (en) 2003-12-31 2008-03-27 Thomas Bader Novel Crystalline Forms of Entacapone and Production Thereof
DK1751087T3 (da) 2004-06-04 2012-07-16 Xenoport Inc Levodopa-derivater og sammensætninger og anvendelser deraf
US20060241183A1 (en) * 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
ATE444746T1 (de) * 2005-06-08 2009-10-15 Orion Corp Eine herstellungsmethode von entacapon- enthaltenden granulaten für orale dosierformen
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
NZ565460A (en) * 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
DK1959948T3 (da) 2005-12-05 2012-08-20 Xenoport Inc Levodopa prodrug-mesylat, sammensætninger deraf og anvendelser deraf
US8741342B2 (en) 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
WO2009108077A2 (en) 2008-02-28 2009-09-03 Bial - Portela & Ca., S.A. Pharmaceutical composition for poorly soluble drugs
ES2476792T3 (es) * 2008-08-22 2014-07-15 Wockhardt Limited Composición farmacéutica de dosis oral unitaria única que comprende levodopa, carbidopa y entacapona o sales de las mismas
NZ591326A (en) * 2008-08-22 2012-12-21 Wockhardt Research Center An extended release pharmaceutical composition of entacapone or salts thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
CA2784819C (en) * 2010-03-04 2018-02-13 Orion Corporation Use of levodopa, carbidopa and entacapone for treating parkinson's disease
JP5551001B2 (ja) 2010-06-22 2014-07-16 株式会社Pfu 摩擦係数推定装置および摩擦係数推定方法
JP2015006373A (ja) * 2014-07-14 2015-01-15 株式会社大都技研 遊技台

Also Published As

Publication number Publication date
US20210085635A1 (en) 2021-03-25
IL221744A (en) 2016-11-30
WO2011107653A3 (en) 2011-11-03
BR112012018256A2 (Direct) 2011-09-09
BR112012018256A8 (pt) 2017-12-19
MX2012010161A (es) 2012-10-03
AU2011222856A1 (en) 2012-07-26
ES2614179T3 (es) 2017-05-30
KR20130006638A (ko) 2013-01-17
CA2784819A1 (en) 2011-09-09
JP5774610B2 (ja) 2015-09-09
CN102781424A (zh) 2012-11-14
WO2011107653A8 (en) 2012-08-02
US11771675B2 (en) 2023-10-03
US10857120B2 (en) 2020-12-08
EA201290865A1 (ru) 2013-02-28
US12521363B2 (en) 2026-01-13
HK1177896A1 (zh) 2013-08-30
EP2542220B1 (en) 2016-11-02
JP2013521263A (ja) 2013-06-10
CN102781424B (zh) 2016-03-30
CA2784819C (en) 2018-02-13
AU2011222856B2 (en) 2015-10-15
WO2011107653A2 (en) 2011-09-09
US20150150839A1 (en) 2015-06-04
US20240050394A1 (en) 2024-02-15
EA026419B1 (ru) 2017-04-28
KR101868326B1 (ko) 2018-06-19
US20130137729A1 (en) 2013-05-30
EP2542220A2 (en) 2013-01-09
ZA201205836B (en) 2014-01-29
JP2015180644A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
MX336187B (es) Metodo para tratar el mal de parkinson.
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
CO6640206A2 (es) Formulación farmaceútica de una solución acuosa de un bufer de ácido glutámico y un anticuerpo
BR112014008036A2 (pt) tratamento de rinite
DOP2017000105A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
NZ713202A (en) Diagnosis and treatments relating to th2 inhibition
MX350046B (es) Tratamientos para trastornos gastrointestinales.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
MX2019009244A (es) FORMULACION PARA ANTICUERPO ANTI -A4ß7.
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
BR112015010396A2 (pt) terapia de combinação
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
AR124078A1 (es) Método para el tratamiento de la enfermedad de parkinson
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
BR112015012497A2 (pt) combinações farmacêuticas
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
UY31826A (es) Compuesto peptídico y su uso
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
NZ591328A (en) Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
RU2012129839A (ru) Комбинация теобромина с деконгестантом и ее применение для лечения кашля